国药之光安罗替尼领衔 中国生物制药13项肺癌成果闪耀世界舞台

鲁网
Aug 06

2025年世界肺癌大会(WCLC)即将在巴塞罗那揭幕,中国生物制药(1177.HK)将以13项安罗替尼研究成果强势登陆。作为中国原研多靶点抗血管生成药物的“国药之光”,安罗替尼在非小细胞肺癌(NSCLC)、小细胞肺癌(SCLC)及恶性胸膜间皮瘤(MPM)等领域的创新疗法将集中亮相,彰显中国生物制药在肺癌精准治疗领域的全球竞争力。攻克肺癌耐药堡垒:安罗替尼组合拳破局本次大会的核心看点聚焦于安罗替尼...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10